MRI staging after neoadjuvant chemotherapy for breast cancer: Does tumor biology affect accuracy?

Annals of Surgical Oncology

Volumn 18, Issue 11, 2011, Pages 3149-3154

  McGuire, Kandace P ^a   Toro Burguete, Jorge ^b   Dang, Hang ^a   Young, Jessica ^c   Soran, Atilla ^a   Zuley, Margarita ^a   Bhargava, Rohit ^a   Bonaventura, Marguerite ^a   Johnson, Ronald ^a   Ahrendt, Gretchen ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b PONCE SCHOOL OF MEDICINE   (Puerto Rico)

^c MERCY HOSPITAL OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; TRASTUZUMAB;

ADULT; AGED; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CONFERENCE PAPER; HUMAN; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MASTECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTIAL MASTECTOMY; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; TRIPLE NEGATIVE BREAST CANCER;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARCINOMA, LOBULAR; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 83055170003     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-1912-z     Document Type: Conference Paper

References (21)

1. Rosen EL, Blackwell KL, Baker JA, et al. Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. Am J Roentgenol. 2003;181(5):1275-82.
2. Jung Kim H, Im Y-H, Han B-K, et al. Accuracy of MRI for estimating residual tumor size after neoadjuvant chemotherapy in locally advanced breast cancer: relation to response patterns on MRI. Acta Oncologica. 2007;46(7):996-1003.
3. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nineyear results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;30(30):96-102.
4. Prati R, Minami CA, Gornbein JA, Debruhl N, Chung D, Chang HR. Accuracy of clinical evaluation of locally advanced breast cancer in patients receiving neoadjuvant chemotherapy. Cancer. 2009;115(6):1194-202.
5. Warren RML, Bobrow LG, Earl HM, et al. Can breast MRI help in the management of women with breast cancer treated by neoadjuvant chemotherapy? Br J Cancer. 2004;90(7):1349-60.
6. Chen J-H, Baek H-M, Nalcioglu O, Su M-Y. Estrogen receptor and breast MR imaging features: A correlation study. J Magn Reson Imaging. 2008;27(4):825-33.
7. Esserman L, Hylton N, Yassa L, Barclay J, Frankel S, Sickles E. Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging. J Clin Oncol. 1999;17(1):110-5.
8. Wasser, Wasser K, Sinn, et al. Accuracy of tumor size measurement in breast cancer using MRI is influenced by histological regression induced by neoadjuvant chemotherapy. Eur Radiol. 2003;13(6):1213-23.
9. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13(8):2329-34.
10. Colleoni M, Viale G, Zahrieh D, et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors. Clin Cancer Res. 2004;10(19):6622-8.
11. Chen JH, Feig B, Agrawal G, et al. MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy. Cancer. 2008;112(1):17-26.
12. Hayes C, Padhani AR, Leach MO. Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging. NMR Biomed. 2002;15(2):154-63.
13. Loo CE, Straver ME, Rodenhuis S, et al. Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. J Clin Oncol. 2011;29(6):660-6.
14. Bhargava R, Dabbs DJ, Beriwal S, et al. Semiquantitative hormone receptor level influences response to trastuzumabcontaining neoadjuvant chemotherapy in HER2-positive breast cancer. Mod Pathol. 2011;24(3):367-74.
15. Bhargava R, Beriwal S, Dabbs DJ, et al. Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases. Cancer. 2010;116(6):1431-9.
16. Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003;21(22):4165-74.
17. Guarneri V, Broglio K, Kau SW, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol. 2006;24(7):1037-44.
18. Choi HK, Cho N, Moon WK, Im SA, Han W, Noh DY. Magnetic resonance imaging evaluation of residual ductal carcinoma in situ following preoperative chemotherapy in breast cancer patients. Eur J Radiol. 2011. doi:10.1016/j.ejrad. 2011.01.013.
19. Hylton N, Blume J, Gatsonis C, Gomez R, Bernreuter W, Pisano E, et al: ACRIN 6657/I-SPY Trial Team. MRI tumor volume for predicting response to neoadjuvant chemotherapy in locally advanced breast cancer: findings from ACRIN 6657/CALGB 150007. 2009 ASCO Annual Meeting, vol 27, Orlando, FL. J Clin Oncol. 2009 (suppl; abstr 529).
20. Sorbero M, Dick A, Beckjord E, Ahrendt G. Diagnostic breast magnetic resonance imaging and contralateral prophylactic mastectomy. Ann Surg Oncol. 2009;16(6):1597-605.
21. Katipamula R, Degnim AC, Hoskin T, et al. Trends in mastectomy rates at the Mayo Clinic Rochester: effect of surgical year and preoperative magnetic resonance imaging. J Clin Oncol. 2009;27(25):4082-8.